Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients

Oncotarget

Volumn 6, Issue 18, 2015, Pages 16653-16662

  Jung, Hyun Ae ^a,b   Maeng, Chi Hoon ^c   Kim, Moonjin ^a   Kim, Sungmin ^a   Jung, Chul Won ^a   Jang, Jun Ho ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Hallym University Medical Center   (South Korea)

^c Kyung Hee University College of Medicine   (South Korea)

Author keywords

Myelodysplastic syndrome; Platelet

Indexed keywords

DECITABINE; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DNA METHYLTRANSFERASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD EXAMINATION; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTE COUNT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; CYTOLOGY; METABOLISM; MORTALITY; MYELODYSPLASTIC SYNDROMES; THROMBOCYTE; TREATMENT OUTCOME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BIOMARKERS, TUMOR; BLOOD PLATELETS; DISEASE-FREE SURVIVAL; DNA MODIFICATION METHYLASES; FEMALE; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; PLATELET COUNT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84937847115     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3914     Document Type: Article

References (25)

1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C and Silverman LR. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higherrisk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10:223-232.
2. Santini V. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes. Expert Rev Hematol. 2009; 2:121-127.
3. Ritchie EK. Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome. Clin Interv Aging. 2012; 7:165-173.
4. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R, 3rd, Shen L, Nimer SD, Leavitt R, Raza A and Saba H. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106:1794-1803.
5. Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE and Issa JP. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007; 109:1133-1137.
6. Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J and Issa JP. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007; 109:265-273.
7. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA and Holland JF. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002; 20:2429-2440.
8. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M and Ferrant A. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of highrisk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000; 18:956-962.
9. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI and Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007; 109:52-57.
10. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT and Kantarjian H. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009; 27:3842-3848.
11. Lee JH, Jang JH, Park J, Park S, Joo YD, Kim YK, Kim HG, Choi CW, Kim SH, Park SK, Park E and Min YH. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. Haematologica. 2011; 96:1441-1447.
12. Moon JH, Kim SN, Kang BW, Chae YS, Kim JG, Baek JH, Park JH, Song MK, Chung JS, Won JH, Lee SM, Joo YD, Kim YK, Kim HJ, Jo DY and Sohn SK. Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment. Ann Hematol. 2010; 89:681-689.
13. Park MJ, Kim HJ, Kim SH, Kim DH, Kim SJ, Jang JH, Kim K, Kim WS and Jung CW. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. Eur J Haematol. 2008; 81:364-373.
14. Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Salanoubat C, Visanica S, Stamatoullas A, Isnard F, Marfaing-Koka A, de Botton S, Chelghoum Y, Taksin AL, Plantier I, Ame S, Boehrer S, Gardin C, Beach CL, Ades L and Fenaux P. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011; 117:403-411.
15. Lubbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, Andre M and Ferrant A. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Br J Haematol. 2001; 114:349-357.
16. Najfeld V, Chen A, Scalise A, Ambinder EP, Fernandez G and Waxman S. Myelodysplastic syndrome transforming to acute promyelocytic-like leukemia with trisomy and rearrangement of chromosome 11. Genes Chromosomes Cancer. 1994; 10:15-25.
17. Traina F, Visconte V, Elson P, Tabarroki A, Jankowska AM, Hasrouni E, Sugimoto Y, Szpurka H, Makishima H, O'Keefe CL, Sekeres MA, Advani AS, Kalaycio M, Copelan EA, Saunthararajah Y, Olalla Saad ST, Maciejewski JP and Tiu RV. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014; 28:78-87.
18. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, Fulton R, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Kandoth C, Baty J, Westervelt P, DiPersio JF, Mardis ER, Wilson RK, Ley TJ and Graubert TA. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011; 25:1153-1158.
19. Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, Yang J, Wang CZ, Chai HY, Qian Z, Xiao GF and Xu WR. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One. 2011; 6:e26906.
20. Cazzola M, Della Porta MG and Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013; 122:4021-4034.
21. Bejar R and Ebert BL. The genetic basis of myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010; 24:295-315.
22. van den Bosch J, Lubbert M, Verhoef G and Wijermans PW. The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res. 2004; 28:785-790.
23. van der Helm LH, Alhan C, Wijermans PW, van Marwijk Kooy M, Schaafsma R, Biemond BJ, Beeker A, Hoogendoorn M, van Rees BP, de Weerdt O, Wegman J, Libourel WJ, Luykx-de Bakker SA, Minnema MC, Brouwer RE, Croon-de Boer F, Eefting M, Jie KS, van de Loosdrecht AA, Koedam J, Veeger NJ, Vellenga E and Huls G. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol. 2011; 155:599-606.
24. Wang J, Yi Z, Wang S and Li Z. The effect of decitabine on megakaryocyte maturation and platelet release. Thromb Haemost. 2011; 106:337-343.
25. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA and Kantarjian H. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108:419-425.